Literature DB >> 3115656

Enhanced production of gamma-interferon by thyroid-derived T cell clones from patients with Hashimoto's thyroiditis.

G F Del Prete1, A Tiri, S Mariotti, A Pinchera, M Ricci, S Romagnani.   

Abstract

T lymphocytes from thyroid infiltrate and peripheral blood (PB) of four patients with Hashimoto's thyroiditis (HT) were analysed at clonal level for their ability to secrete interleukin 2 (IL-2) and gamma-interferon (gamma-IFN). As controls, T cell clones from PB of four normal donors and from spleen of two trauma victims were used. While no abnormality was found in the capacity to produce IL-2, the proportion of gamma-IFN-producing (IFN-P) T cell clones derived from HT infiltrates was significantly higher (P less than 0.0005) than that of IFN-P clones derived from normal or patient PB. Most of CD4+ and CD8+ IFN-P clones from thyroid infiltrates, as well as a proportion of CD4+ PB-derived clones of patients with HT, released higher amounts of gamma-IFN than control clones. A relationship could be demonstrated between high gamma-IFN production and natural killer (NK) activity in T cell clones from thyroid and PB of HT patients. In fact, the percentage of IFN-P clones with NK potential (NK+) was remarkably higher (P less than 0.0005) in thyroid infiltrates than in normal spleen or PB. The proportion of IFN-P NK+ clones from patient PB was also significantly increased (P less than 0.02) but, unlike thyroid-derived clones in which the majority of IFN-P NK+ clones were CD8+, most PB-derived IFN-P NK+ clones from the same patients expressed the CD4+ phenotype. Almost all thyroid NK+ clones could be triggered to produce more gamma-IFN, while gamma-IFN synthesis by NK-negative thyroid clones was comparable to that of control clones. In view of the multiple effects ascribed to gamma-IFN in the cascade of events leading to immune responses, the abnormal potential to gamma-IFN secretion shown by intrathyroidal T lymphocytes may be of importance in the pathogenesis of autoimmune thyroiditis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115656      PMCID: PMC1542409     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Thyroid-infiltrating T lymphocyte subsets in Hashimoto's thyroiditis.

Authors:  R Jansson; T H Tötterman; J Sällström; P A Dahlberg
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

2.  Immunohistochemical characterization of intrathyroid lymphocytes in Graves' disease. Interstitial and intraepithelial populations.

Authors:  J B Margolick; S M Hsu; D J Volkman; K D Burman; A S Fauci
Journal:  Am J Med       Date:  1984-05       Impact factor: 4.965

3.  Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease.

Authors:  S Romagnani; G F Del Prete; E Maggi; G Bellesi; G Biti; P L Rossi Ferrini; M Ricci
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

4.  Thyroid autoantibody synthesis by cultures of thyroid and peripheral blood lymphocytes. I. Lymphocyte markers and response to pokeweed mitogen.

Authors:  S M McLachlan; A M Dickinson; A Malcolm; J R Farndon; E Young; S J Proctor; B R Smith
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

5.  Gamma-interferon is one of several direct B cell-maturing lymphokines.

Authors:  C L Sidman; J D Marshall; L D Shultz; P W Gray; H M Johnson
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

6.  Role of gamma-interferon in antibody-producing responses.

Authors:  H J Leibson; M Gefter; A Zlotnik; P Marrack; J W Kappler
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

7.  Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity.

Authors:  T Hanafusa; R Pujol-Borrell; L Chiovato; R C Russell; D Doniach; G F Bottazzo
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

8.  Secretion of immune interferon and generation of cytotoxic T cell activity in nude mice are dependent on interleukin 2: age-associated endogenous production of interleukin 2 in nude mice.

Authors:  J R Klein; M J Bevan
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

9.  Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations.

Authors:  A Moretta; G Pantaleo; L Moretta; M C Mingari; J C Cerottini
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

10.  Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses.

Authors:  J Y Djeu; N Stocks; K Zoon; G J Stanton; T Timonen; R B Herberman
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  11 in total

1.  Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease.

Authors:  C H Nielsen; L Hegedüs; K Rieneck; A C Moeller; R G Q Leslie; K Bendtzen
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Cytokines, thyroid autoantibody synthesis and thyroid cell survival in culture.

Authors:  S M McLachlan; J Taverne; M C Atherton; A Cooke; S Middleton; C A Pegg; F Clark; B Rees Smith
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

3.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease.

Authors:  P Parronchi; P Romagnani; F Annunziato; S Sampognaro; A Becchio; L Giannarini; E Maggi; C Pupilli; F Tonelli; S Romagnani
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

4.  Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis.

Authors:  B Kristensen; L Hegedüs; H O Madsen; T J Smith; C H Nielsen
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

5.  Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7.1 costimulatory molecule.

Authors:  G Pesce; N Fiorino; A M Riccio; P Montagna; G Torre; C Salmaso; V Altrinetti; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

6.  Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines.

Authors:  R J Mullins; S B Cohen; L M Webb; Y Chernajovsky; C M Dayan; M Londei; M Feldmann
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  The self-antigen, thyroglobulin, induces antigen-experienced CD4+ T cells from healthy donors to proliferate and promote production of the regulatory cytokine, interleukin-10, by monocytes.

Authors:  Claus H Nielsen; Marcel P Galdiers; Chris J Hedegaard; R Graham Q Leslie
Journal:  Immunology       Date:  2009-10-21       Impact factor: 7.397

8.  IL-10 expression in thyroid glands: protective or harmful role against thyroid autoimmunity?

Authors:  J R de la Vega; J C Vilaplana; A Biro; L Hammond; G F Bottazzo; R Mirakian
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

9.  Frequency and Distribution of DNA fragmentation in Hashimoto's thyroiditis and development of papillary thyroid carcinoma.

Authors:  Z Jiang; L Savas; N A Patwardhan; J Wuu; A Khan
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

10.  Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Authors:  Ove Bruland; Øystein Fluge; Lars A Akslen; Hans G Eiken; Johan R Lillehaug; Jan E Varhaug; Per M Knappskog
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.